Sex Differences in the Use of Statins in Community Practice: Patient and Provider Assessment of Lipid Management Registry

  • Michael G. Nanna
  • , Tracy Y. Wang
  • , Qun Xiang
  • , Anne C. Goldberg
  • , Jennifer G. Robinson
  • , Veronique L. Roger
  • , Salim S. Virani
  • , Peter W.F. Wilson
  • , Michael J. Louie
  • , Andrew Koren
  • , Zhuokai Li
  • , Eric D. Peterson
  • , Ann Marie Navar

Research output: Contribution to journalArticlepeer-review

249 Citations (Scopus)

Abstract

Background: Female patients have historically received less aggressive lipid management than male patients. Contemporary care patterns and the potential causes for these differences are unknown. Methods and Results: Examining the Patient and Provider Assessment of Lipid Management Registry - a nationwide registry of outpatients with or at risk for atherosclerotic cardiovascular disease - we compared the use of statin therapy, guideline-recommended statin dosing, and reasons for undertreatment. We specifically analyzed sex differences in statin treatment and guideline-recommended statin dosing using multivariable logistic regression. Among 5693 participants (43% women) eligible for 2013 American College of Cardiology/American Heart Association Cholesterol Guideline-recommended statin treatment, women were less likely than men to be prescribed any statin therapy (67.0% versus 78.4%; P<0.001) or to receive a statin at the guideline-recommended intensity (36.7% versus 45.2%; P<0.001). Women were more likely to report having previously never been offered statin therapy (18.6% versus 13.5%; P<0.001), declined statin therapy (3.6% versus 2.0%; P<0.001), or discontinued their statin (10.9% versus 6.1%; P<0.001). Women were also less likely than men to believe statins were safe (47.9% versus 55.2%; P<0.001) or effective (68.0% versus 73.2%; P<0.001) and more likely to report discontinuing their statin because of a side effect (7.9% versus 3.6%; P<0.001). Sex differences in both overall and guideline-recommended intensity statin use persisted after adjustment for demographics, socioeconomic factors, clinical characteristics, patient beliefs, and provider characteristics (adjusted odds ratio, 0.70; 95% CI, 0.61-0.81; P<0.001; and odds ratio, 0.82; 95% CI, 0.73-0.92; P<0.01, respectively). Sex differences were consistent across primary and secondary prevention indications for statin treatment. Conclusions: Women eligible for statin therapy were less likely than men to be treated with any statin or guideline-recommended statin intensity. A combination of women being offered statin therapy less frequently, while declining and discontinuing treatment more frequently, accounted for these sex differences in statin use.

Original languageEnglish (US)
Article numbere005562
JournalCirculation: Cardiovascular Quality and Outcomes
Volume12
Issue number8
DOIs
Publication statusPublished - 1 Aug 2019
Externally publishedYes

Keywords

  • primary prevention
  • secondary prevention
  • sex
  • sex characteristics
  • women

Fingerprint

Dive into the research topics of 'Sex Differences in the Use of Statins in Community Practice: Patient and Provider Assessment of Lipid Management Registry'. Together they form a unique fingerprint.

Cite this